The Lancet September 06, 2026

Induction and consolidation atezolizumab with stereotactic body radiation therapy versus radiation alone in high-risk, early-stage non-small-cell lung cancer (SWOG/NRG S1914): a multicentre, open-label, superiority, phase 3, randomised controlled trial

Megan E Daly, Charles B Simone 2nd, Mary W Redman, Ming-Hui Hsieh, Paul J Hesketh, et al.

Bottom Line

The phase 3 SWOG/NRG S1914 trial demonstrated that adding the immune checkpoint inhibitor atezolizumab to stereotactic body radiation therapy (SBRT) in high-risk, early-stage, medically inoperable non-small-cell lung cancer increased toxicity without improving overall survival.

Key Findings

1. The trial was stopped early for futility at the interim analysis.
2. At a median follow-up of 24.8 months, the addition of atezolizumab to SBRT did not improve overall survival (HR 1.04, 95% CI 0.69-1.58, one-sided p=0.58).
3. The two-year overall survival rate was identical in both treatment arms (82%).
4. Grade 3 or higher adverse events were substantially more common in the atezolizumab combination group compared to the SBRT alone group (12% vs. 3%).
5. There were two treatment-related deaths due to respiratory complications in the atezolizumab arm.

Study Design

Design
RCT
Open-Label
Sample
402
Patients
Duration
24.8 mo
Median
Setting
Multicenter, US
Population Patients with medically inoperable or surgery-refusing early-stage (T1-T3N0M0, ≤7 cm) non-small-cell lung cancer with at least one high-risk factor for recurrence.
Intervention Atezolizumab (1200 mg every 21 days for up to 8 cycles; administered as induction, concurrent, and consolidation) plus stereotactic body radiation therapy (SBRT, 3-8 fractions).
Comparator Stereotactic body radiation therapy (SBRT) alone.
Outcome Overall survival (OS)

Study Limitations

The trial was terminated early due to futility, which precludes the evaluation of long-term efficacy and late-onset toxicities.
The open-label design introduces a risk of bias in the reporting and management of adverse events.
The study population predominantly consisted of older, medically inoperable patients (median age 72.8 years), potentially limiting generalizability to fitter patients with early-stage disease who refuse surgery.

Clinical Significance

These findings establish that stereotactic body radiation therapy (SBRT) alone remains the standard of care for early-stage, medically inoperable non-small-cell lung cancer. The data strongly argue against the off-label use of concurrent or adjuvant immune checkpoint inhibitors with SBRT in this population, as the combination provides no survival benefit and exposes patients to unnecessary immune-related and respiratory toxicities.

Historical Context

Following the landmark PACIFIC trial, which established the survival benefit of consolidation durvalumab after definitive chemoradiation in unresectable stage III NSCLC, there was widespread enthusiasm for integrating immunotherapy with radiation in earlier stages of the disease. Preclinical models strongly suggested that the high doses per fraction used in SBRT could induce immunogenic cell death and synergize with PD-L1 blockade. However, the SWOG/NRG S1914 trial challenged this hypothesis clinically, showing that the mechanistic synergy observed in the laboratory does not translate to a survival benefit in high-risk early-stage disease.

Guided Discussion

High-yield insights from every perspective

Med Student
Medical Student

What is the mechanism of action of atezolizumab, and what is the theoretical rationale for combining an immune checkpoint inhibitor with stereotactic body radiation therapy (SBRT) in early-stage lung cancer?

Key Response

Atezolizumab is a monoclonal antibody that inhibits PD-L1, preventing it from binding to PD-1 and thereby removing the brakes from the anti-tumor T-cell response. The theoretical rationale for adding it to SBRT is based on radiation inducing immunogenic cell death, which releases tumor neoantigens and pro-inflammatory cytokines. This is thought to prime the immune system and potentially synergize with checkpoint inhibitors to eradicate systemic micrometastases, a phenomenon related to the abscopal effect.

Resident
Resident

For a patient with early-stage, medically inoperable non-small-cell lung cancer (NSCLC), what remains the standard of care in light of the SWOG/NRG S1914 trial results, and what primary toxicities should you counsel the patient about?

Key Response

SBRT alone remains the standard of care for early-stage, medically inoperable NSCLC. The S1914 trial showed that adding atezolizumab did not improve overall survival but did increase toxicity. Residents must counsel patients receiving SBRT about localized toxicities such as radiation pneumonitis, fatigue, chest wall pain, and rib fractures, while avoiding the added risks of immune-related adverse events like autoimmune pneumonitis or endocrinopathies associated with atezolizumab.

Fellow
Fellow

The PACIFIC trial established consolidation durvalumab as standard of care after chemoradiation in Stage III NSCLC. Why might the combination of atezolizumab and SBRT in the S1914 trial have failed to demonstrate a similar survival benefit in early-stage disease?

Key Response

Several factors could explain this discrepancy. Early-stage NSCLC treated with SBRT has a significantly lower systemic micrometastatic disease burden and less extensive antigen presentation compared to locally advanced Stage III disease. Furthermore, the S1914 trial did not utilize concurrent systemic chemotherapy, which may be necessary to induce sufficient immunogenic cell death and prime the T-cell response for checkpoint inhibitors to confer a measurable survival benefit. Additionally, competing non-cancer mortality in the medically inoperable population may dilute any small cancer-specific survival gains.

Attending
Attending

How does the negative result of the SWOG/NRG S1914 trial serve as a critical teaching point regarding the premature adoption of theoretically synergistic systemic therapies into highly effective localized treatment paradigms?

Key Response

This trial is a classic cautionary tale reminding clinicians that 'more is not always better.' SBRT alone yields excellent local control and favorable survival rates in early-stage inoperable NSCLC. Attempting to improve upon this with immunotherapy based on promising preclinical synergy or extrapolated data from advanced stages can introduce overlapping toxicities (like severe pneumonitis) that compromise patient quality of life and survival. It reinforces the necessity of waiting for definitive phase 3 data before altering standard practice.

Scholarly Review

Critical appraisal through the lens of expert reviewers and guideline development

PhD
PhD

In the context of the open-label design used in the SWOG/NRG S1914 trial, how might the absence of a placebo control for the atezolizumab arm introduce systematic bias into both toxicity reporting and the overall survival endpoint?

Key Response

An open-label design introduces observer and reporting bias, particularly for subjective or overlapping adverse events like fatigue or low-grade pneumonitis, which may be over-attributed to the experimental arm. More importantly, knowledge of the patient's treatment assignment can influence subsequent lines of therapy upon progression. Physicians might withhold future checkpoint inhibitors from patients in the experimental arm while preferentially administering them to the control arm upon relapse, potentially confounding the overall survival endpoint through crossover effects.

Journal Editor
Journal Editor

As a peer reviewer evaluating the S1914 trial, how would you critically appraise the criteria used to define 'high-risk' early-stage NSCLC, and how might heterogeneity within this cohort threaten the trial's statistical power to detect an overall survival benefit?

Key Response

A critical reviewer would flag the operational definition of 'high-risk.' If the criteria (e.g., tumor size, central location, SUV max) captured a highly heterogeneous group where the primary risk of death was actually due to severe cardiopulmonary comorbidities (the very reason they are medically inoperable) rather than cancer progression, the trial would suffer from a high rate of competing mortality events. This dilutes the statistical power to detect an oncology-specific overall survival benefit, making a negative result almost inevitable unless the effect size was massive.

Guideline Committee
Guideline Committee

Based on the findings of SWOG/NRG S1914, what specific update should be drafted for the ASTRO and NCCN guidelines regarding the systemic management of medically inoperable, early-stage NSCLC receiving SBRT?

Key Response

Current guidelines generally recommend SBRT alone for medically inoperable early-stage NSCLC. Based on the Level 1 evidence from S1914 demonstrating increased toxicity without an overall survival benefit, the guideline committee should draft a Strong Recommendation against the routine addition of induction, concurrent, or consolidation immune checkpoint inhibitors to SBRT in this specific patient population outside of a clinical trial, formally reaffirming SBRT monotherapy as the definitive standard of care.

Clinical Landscape

Noteworthy Related Trials

2017

PACIFIC Trial

n = 713 · NEJM

Tested

Consolidation durvalumab for up to 12 months

Population

Patients with stage III unresectable NSCLC without progression after chemoradiotherapy

Comparator

Placebo

Endpoint

Progression-free survival and overall survival

Key result: Durvalumab significantly improved both progression-free survival and overall survival compared to placebo.
2019

PEMBRO-RT Trial

n = 76 · JAMA Oncol

Tested

SBRT prior to pembrolizumab

Population

Patients with advanced NSCLC

Comparator

Pembrolizumab alone

Endpoint

Overall response rate at 12 weeks

Key result: Combining SBRT with pembrolizumab doubled the overall response rate from 18 percent to 36 percent compared to pembrolizumab alone.
2021

IMpower010 Trial

n = 1005 · Lancet

Tested

Adjuvant atezolizumab for 1 year

Population

Patients with completely resected stage IB-IIIA NSCLC post-chemotherapy

Comparator

Best supportive care

Endpoint

Disease-free survival

Key result: Atezolizumab significantly improved disease-free survival compared with best supportive care in early-stage NSCLC.

Tailored to your role

Want this tailored to you?

Add your specialty or training stage to get role-specific takeaways and more questions.

Personalize this analysis